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Summary 
B cell chronic lymphocytic leukemia (CLL) is a malignancy of the CD5 + B cells. Prior studies 
indicated that CLL B cells generally express immunoglobulin (Ig) V. and VL genes with little 
or no somatic mutations. However, a recent report indicated that V.251, one of three VH genes 
belonging to the VH5 subgroup (e.g., V.251, V.32, and V815), not only is frequently rearranged 
in this disease, but also has extensive and selective mutations when expressed by CLL B cells. 
The extent and nature of these mutations contrasts markedly from the low level of mutations 
noted in V.5 genes used by normal B cells or other Ig V genes found expressed in CLL. To 
determine whether this difference reflects a unique property of VH251 or a previously 
unrecognized subgroup of CLL, we examined for V.5 Ig gene rearrangements in leukemia cells 
from 68 patients that satisfied clinical and diagnostic riteria for CD5 § B cell CLL. Southern 
blot hybridization studies with probes for V.251 and the J. locus revealed that only 7 (10%) 
of the 68 monoclonal CLL cell populations had undergone Ig gene rearrangement i volving 
V.5 genes. Two (3%) were found to have functionally rearranged V.5 genes that shared >198% 
sequence homology with 5-2R1, a V~251 gene isolated from a pre-B cell acute lymphocytic 
leukemia. The other five CLL (7%) had functionally rearranged V.5 genes that each shared 
t>99% nucleic acid sequence homology with a germline V.32 isolated from human sperm DNA. 
These data indicate that V8251 or V.32 also may be expressed by CD5 § CLL B cells with little 
or no somatic mutation. These findings contrast with a recently published study on V.5 gene 
expression i  B CLL and contest he hypothesis that extensive somatic mutation is a common 
property of the V~5 genes used in this disease. Further work to define the clinical and/or 
phenotypic characteristics of patients with leukemia cells that express mutated versus nonmutated 
Ig V genes may reveal subsets of CLL that possibly differ in their cytogenesis, etiopathogenesis, 
and/or clinical behavior. 
B cell chronic lymphocytic leukemia (CLL) 1, the most 
common adult leukemia in Western societies, may be 
considered a malignancy of "B-1 B cells", formerly referred 
to as CD5 (or Lyl) B cells (for reviews ee references 1 and 
2). Generally, the leukemia cells in this disease coexpress CD5, 
pan-B cell surface antigens and surface Ig. In addition, common 
B cell CLL may share additional characteristics with those 
of normal human B-1 B cells, such as the frequent produc- 
tion of polyreactive autoantibodies (3-5), expression of my- 
elomonocytic surface antigens (6-10), low-level expression 
of CD20 (11, 12), or the ability to form rosettes with mouse 
erythrocytes (13, 14). 
We found that the leukemia cells from many CLL patients 
1 Abbreviations used in this~per: CLL, chronic lymphocytic leukemia; CRI, 
cross-reactive diotype; FR, framework egion. 
express Ig that bear one or more autoantibody-associated cross- 
reactive idiotypes (CRIs) (15-18). Evaluation of the molec- 
ular basis for such CRIs revealed that each may be a serologic 
marker for expression of a conserved Ig V gene with limited 
or no somatic mutation (19-21). In addition, we and others 
find that CLL B cells not selected for expression of a CRI 
also may express Ig V genes that share extensive homology 
(>97%) with other known germline Ig V genes (18, 22-26). 
Finally, normal or malignant murine B-1 B cells generally 
also express restricted, if not unique, repertoires ofIg V genes 
that display little or no somatic mutation (27-30). Collec- 
tively, these studies imply that B-1 B cell malignancies use 
restricted repertoires of Ig V genes that have not diversified 
substantially from the germline DNA. 
However, there is an apparent exception to this general- 
ization. Humphries et al. (31) noted that the leukemia cells 
from related CLL patients expressed extensively mutated Ig 
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V. genes belonging to the V.5 subgroup. In addition, they 
noted that 30% of patients with B cell CLL have rearranged 
V. genes that belong to this subgroup. These same investi- 
gators examined 11 additional CLL B cell populations that 
also expressed Ig encoded by V.5 genes (32, 33). Since prior 
studies indicated that Ig V. genes of this small subgroup are 
highly conserved and nonpolymorphic (34), these investigators 
compared the primary nucleic acid sequences ofthe expressed 
VH genes with that of known V.5 genes. In 10 of 11 CLL, 
they found the expressed V.5 genes to differ substantially 
from those of known germline sequences. Importantly, non- 
conservative nucleic acid base differences were found clustered 
primarily in sequences encoding the Ig CDRs which form 
the pocket of the presumed Ig antigen-combining site. Such 
substitutions often are noted in Ig selected in an antigen- 
driven secondary immune response. Accordingly, it appears 
that these CLL express omatically mutated Ig V genes that 
have been selected for their ability to bind some unknown 
antigen(s). 
It is not certain whether these leukemias represent a dis- 
tinct subset of CLL or whether they express mutated Ig V 
gene because they use Ig V. genes of the V.5 subgroup. The 
V.5 gene subgroup is relatively small, consisting of only 
two functional genes (V.251 and V832) and one pseudogene 
(V.15) (31, 35, 36). The V,251 gene is distinctive in that 
it is transcribed at relatively high levels in the germline non- 
rearranged configuration (36). Conceivably, such transcrip- 
tional activity could affect higher rates of Ig gene rearrange- 
ment and/or somatic mutation of this V. gene in CLL B 
cells or leukemia B cell precursors. Alternatively, despite also 
being CD5 + (32, 33), the CLL cells examined by these in- 
vestigators may constitute a discrete subset of chronic leukemia 
that differs from that of other B cell CLL in its physiology 
of Ig gene expression. For these reasons, we decided to ex- 
amine for V,5 gene rearrangements in the leukemia cells 
from 68 patients that satisfied iagnostic and clinical criteria 
for B cell CLL. 
of DNA was digested with fivefold excess of restriction enzyme 
in appropriate buffers and then loaded onto a 0.8% agarose gel 
(GIBCO BRL, Gaithersburg, MD). After electrophoresis for660 
volt-hours, the size-separated DNA was transferred onto nylon for 
Southern blot hybridization with radiolabeled probes as described 
(35, 44). Final washing conditions consisted of two 20-min washes 
at 65~ in 0.2x SSC in 0.1% NaDodgO4 (V,251 probe), or 0.1x 
SSC in 0.1% NaDodSO4 (J. probe) (lx SSC, 0.15 M NaC1/ 
0.015 M sodium citrate, pH 7.0). 
Probes and Oligonucleoticles. The probe for V,251 consisted of 
a 1.0-kb XbaI/PstlI fragment of WS1 (35) that included most of 
the V.251 coding region along with a few hundred bp of the 5' 
flanking region. The J. probe consisted of a 2.1-kb Sau3A frag- 
ment spanning the genomic DNA of J.2 through J.6. DNA 
probes were radiolabeled toasp act of 109 cpm//zg with a_[np] 
CTP (New England Nuclear, Boston, MA) via random hexamer 
priming (45). Oligonucleotides and probes uch as the V.5 third 
framework region (FR) probe (5' GCA GAC TTC TCC TCA GG 
3') and the B-globin internal probe (5' GCA GAC TTC TCC TCA 
GG 3') were synthesized as described (15). These probes were 5' 
end-hbeled using -y-[32p]ATP and polynucleotide kinase to asp act 
of 2 x 107 cpm/pmol, as described (46). 
PCR Amplification ofGenomic DNA. 1 #g of genomic DNA 
was amplified using the PCP, technique as described (44). Primers 
corresponding to the sense strand of the leader sequence of the 
V.251 gene (dGCGAATTCAAGCTTCAACCGCCATCCTC- 
GCC) and the antisense strand of a J. consensus sequence (dGG- 
CGAATTCACCTGAGGAGACRGTGACC) (R, G/A) were used 
to amplify V.5 genes that were juxtaposed to J. through Ig gene 
rearrangement. To control for template fidelity, PCR using oligo- 
nucleotides dACACAACTGTGTTCACTAGC and dCAACTT- 
CATCCACGTTCACC was performed toamplify the ~-globin gene 
in the genomic DNA of all samples, as described (20). 
Cloning and DNA Sequencing. The amplified DNA segments 
were digested with HindlII and EcoRI to cut the linkers incorpo- 
rated into the oligonucleotide primers, purified and ligated into 
a HindlII/EcoRI-cut pUC19 vector (Bluescribe; Stratagene, La 
Jolla, CA) for transformation fcompetent Escherichia coli, as de- 
scribed (44). Plasmids containing the insert were isolated for double- 
strand (ds)DNA sequencing as described (47, 48). 
Materials and Methods 
Patients. Peripheral b ood samples were obtained from 68 pa- 
tients fulfilling diagnostic and immunophenotypic criteria for 
common B cell CLL at the UCSD Medical Center, the Veteran's 
Administration Hospital, or the Scripps Clinic and Research Foun- 
dation (all in La Jolla, CA; 37-41). The median age of the patients 
was 63, ranging from 41 to 79 years. The patients were heteroge- 
neous with respect to clinical stage (ranging from Rai stage 0 to 
stage IV) and prior therapy for CLL. 52 (76%) of the patients were 
male, reflecting the known 5:2 male/female bias in the prevalence 
of common Bcell CLL (42). Each patient is assigned a unique three- 
letter identifier (listed in capital etters). 
Flow Cytometry. Direct immunofluorescence analyses of leu- 
kemia cells were performed using a flow cytometer (FACScan~; 
Becton Dickinson & Co., San Jose, CA) as described (38). PE- or 
fluorescein-conjugated mAbs specific for CD20, CD19, or CD5, 
and their respective isotype control mouse IgG, were purchased 
from Becton Dickinson & Co. Other mAbs were as described (43). 
DNA Isolation and Southern Blotting. Genomic DNA was iso- 
lated from the leukemia cells as described (44). A total of 10/zg 
Results 
Flow Cytometric Analyses. Direct immunofluorescence anal- 
yses of the mononuclear cells from each subject substantiated 
the diagnosis of common B cell CLL, indicating that >70% 
(mean 92%, range 71-99%) of the lymphocytes in each blood 
sample coexpressed pan-B cell surface antigens, CD5 and K 
or X L chains (data not shown). Of the 68 leukemia cell popu- 
lations studied, 39 (57%) expressed Ig K L chains and 29 (43%) 
expressed ~ L chains. 
Southern Blot Analyses. Genomic DNA isolated from each 
of the 68 samples was digested with BamHI and HindlII 
for Southern blot hybridization analysis. Hybridization of 
filter-immobilized DNA with the radiolabeled J. probe re- 
vealed each to have monoclonal Ig gene rearrangements (Fig. 
1, and data not shown). 45 (65%) of the samples had two 
detectable J. gene rearrangements, whereas the remaining 
23 samples each had only one nongermline J. restriction 
fragment. 
Using the V.251 probe, we found that most DNA 
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Figure 1. Southern blot analysis of genomic leu- 
kemia cell DNA digested with BamHl and HindlII 
restriction e zymes and hybridized sequentially with 
radiolabeled probes for V,251 (lane A) and human J. 
region (lane B). (Left) The kb of the nonrearranged 
bands containing V.251 (Z5 kb), VH32 (3.2 kb), and 
VH15 (1.5/1.4 kb). (~') The rearranged VH5 gene 
identified ineach lane A of samples 2-7. The samples 
in each lane are: NOM (lane 1), HAN (lane 2), CAV 
(lane 3), HOW (lane 4), PET (lane 5), ANG (lane 
6), and KER (lane 7). 
samples had the germline V.5 gene pattern of placental 
DNA (Fig. 1, lane 1A, and data not shown) (31). The 
V,251, V.32, and V815 genes are contained in the 7.5-, 3.2-, 
and 1.4/1.5-kb fragments, respectively (e.g., Fig. 1, lane LA 
[NOM]). These four bands were identified in 37 (54%) of 
the 68 samples tested. In 26 (39%) of the samples, the 3.2-kb 
V832 gene fragment was not detected, suggesting hat the 
germline V~32 genes of both alleles were lost, possibly 
through Ig gene rearrangement. However, previous studies 
demonstrated that the germline DNA of many individuals 
actually lack this 3.2-kb BamHI/HindlII V.32 restriction 
fragment (31). As such, the absence of this band in these CLL 
DNA samples instead may be due to genetic polymorphism. 
In 7 (10%) of the 68 CLL DNA samples, we identified 
nongermline bands with the V.251 probe. In all cases, these 
nongermline bands matched those detected using the human 
J. probe, arguing that V,5 genes within these CLL had un- 
dergone Ig gene rearrangement (Fig. 1). Two (3% of the total) 
had rearranged BamHI/HindlII fragments of 8.5 kb, sug- 
gesting that these CLL samples each ad a rearranged V.251 
juxtaposed to J~4 (e.g., Fig. 1, lane 2A [HAN]) (31). In the 
other five samples, we detected nongermline BamHI/HindlII 
fragments of3.0-4.0 kb that matched rearranged bands that 
hybridized with the human J. probe (Fig. 1, samples 3 
[CAV], 4 [HOW], 5 [PET], 6 [ANG], and 7 [KER]). How- 
ever, such BamHI/HindlII restriction fragments should be 
too small to contain a rearranged V,251 gene juxtaposed 
with any J, gene segment, unless alternative BamHI or 
HindlII restriction sites were introduced into or around this 
gene through Ig gene rearrangement, somatic mutation, 
and/or genetic polymorphism. More likely, these relatively 
small restriction fragments contain V.32 rearranged with ei- 
ther J,4 (HOW, Fig. 1, lane 4A), J.5 (ANG and KER, Fig. 
1, lanes 6/t and 7A) or JH6 (CAV and PET, Fig. 1, lanes 3A 
and 5A), respectively. 
Sequence Analyses of Rearranged V.5 Genes. To examine 
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the V,5 genes juxtaposed to J. through Ig gene rearrange- 
ment, we performed the PCR on the genomic DNA from 
each of the 68 samples using primers corresponding to the 
sense strand of the V~251 leader and the antisense strand of 
a J, consensus equence. We found that only the CLL 
samples noted to have V.5 gene rearrangements by Southern 
analyses yielded PCR products that hybridized with either 
an oligonucleotide corresponding to thethird FR of V.251 
or the genomic V8251 probe (data not shown). On the 
other hand, each ofthe 68 DNA samples yielded 112-bp gene 
fragments in control PCR using ~/-globin specific primers 
(data not shown). Therefore, the inability to amplify V.5 
Ig gene rearrangements i  the other DNA samples could not 
be ascribed to inadequate template quality or nonspecific PCR 
inhibitors. 
Nucleic acid sequence analyses confirmed that each of these 
seven CLL DNA samples contained rearranged V~5 genes 
(Figs. 2 and 3). The two CLL DNA samples reasoned to 
have possible V,251 gene rearrangements by Southern 
(DOB and HAN) were found to have rearranged V,5 genes 
that shared i>98% sequence homology with 5-2R1, a Va251 
gene isolated from an acute pre-B cell leukemia (49) (Fig. 
2). The V. gene of DOB is identical to that of 5-2R1. The 
V. of HAN, on the other hand, differs from 5-2R1 by four 
nucleotides in the first Ig FR and two in the third Ig FR 
(Fig. 2). However, only two of these base differences are non- 
conservative, resulting in a Gly -- Arg substitution at posi- 
tion 26 and a Ser -~ Arg change at position 82B (numbering 
according to Kabat et al. [50]). The rearranged V.5 genes 
of the other five CLL (e.g., CAV, HOW, PET, ANG, and 
KER) were found to share i>99% nucleic acid sequence ho- 
mology to a germline VH32 gene isolated from human 
sperm DNA (Fig. 2) (31, 51). Except for a conservative base 
change in the codon for the amino acid at position 7 in the 
first Ig FR, CAV and HOW are identical to VH32. The 
other three V. genes also differed from V.32 by one (PET) 
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5 -2R I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
DOB . . . . . .  ' ,  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
HAH . . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
UH32 . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
CAU . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
HOW . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . .  [ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
PET . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
AHG . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
KER . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . . . . . . .  , . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Figure 2. Nucleic acid sequences of rearranged V.5 genes and V.32 compared with VH251. The complete sequence of V.251 is provided (31). (*) 
Introduces gaps to maximize sequence homologies among the compared sequences. Above the V.251 sequence are the deduced amino acid sequence 
and descriptors indicating the leader sequence, the intervening sequence of the first intron, or the Ig CDR1 and CDR2. The numbers above the deduced 
amino acid sequence refer to the Ig amino acid residues according to Kabat et al. (50). Below the V.251 sequence are other V.5 genes, as indicated 
by the sequence names (left). (-) Indicates homology with V.251 at a given nucleic acid base position. 
or two (ANG or KEk) base changes in the intron (marked 
intervening sequence, Fig. 2). 
Each of the rearranged V.5 Ig genes detected in our 
survey had a unique sequence ncoding the third CDR 
(CDR3) (Fig. 3). The CDR3 sequence ofeach had stretches 
with high homology to known germline D. and J, gene 
segments (50, 52). The sequences ncoding the CDIk3 of 
PET, CAV, or HOW each ad highest homology with DN1. 
Those of DOB or KER had the highest homology with Dxpl, 
whereas the CDR3 sequence of HAN or ANG had the highest 
homology with DA4 or DK1, respectively. Of the seven dis- 
parate CDRs, we deduce that three (DOB, HOW, and HAN) 
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N-D-N JH  Segments  
Ser I leSerSerSerGlyTyrTyrSer  
DOB TCGATCTCCAGTAGTGGTTATTACTCT 
Dxpl "C ......... 
AsnPheAspTyrTrpGlyG lnGlyThrLeuVa lThrVa lSerSer  
AACTTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCT~ DOB 
T . . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . . . . . . .  JH 4 
G ln I leA laGly I leA laA laA laGlyMetTrpGlyPro  
CAV CAAATCGCCGGTATAGCAGCAGCTGGTATGTGGGGTCCA 
DNI . . . . . . . . . . . . . . . . . . .  
TyrTyrTyrTyrTyrMetAspVa lTrpGlyLysGlyThrThrVa lThrVa lSerSer  
TACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA CAV 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  GC . . . . . . . . . . . . . . . . . . . . . . . . . .  JH6 
GluGlnTrpLeuValLeuSer  
HOW GAGCAGTGGCTGGTACTGTCC 
DNI T ..... CA ........ 
AsnPheAspTyrTrpGlyG lnGlyThrLeuVa lThrVa lSerSer  
AATTTTGACTAC~CAGGGAACCCTGGTCACCGTCTCCTCA HOW 
T-C . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . . . . . . .  JH 4 
LeuTyrGlyAspPheSerThrVal  
HAN C TT TACGGTGACT T TC TACAGTT 
DA4 ....... 
AspTyr  TrpGlyGl  nGlyThr  LeuVaiThrVal  Se rSer 
GACTAC~CAGGGAACCC TGGTCACCGTCTCCTCA HAN 
. . . . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . . . . . . .  JH4 
LeuLeuTyrGlyA laA laA laA laTrpGly  
PET C TATTGTATGGAGCAGCAGCTGCC ~ 
DNI ........... 
TyrTyrTyrTyrTyrMetAspVa lTrpGlyLysGlyThrThrVa iThrVa lSerSer  
TAC TAC TACTAC TACATGGAOG TC ~AAAGGGACAACGGTCACCGTCTCCTCA PET 
............ GGT . . . . . . . . . . . . . .  GC ....... C . . . . . . . . . . . . . . . . . .  JH6 
HisThrValGlyGlyTyrSerGlyCys 
ANG CACACAGTGGGAGGATATAGTGGCTGT 
DKI . . . . . . . . . . . . . . .  
SerG lnSerTrpGlyGlnGlyThrLeuVa lThrVa lSerSer  
TCCCAGTCC ~ CAAGGAACCTTGGTCACC GTCTCCTCA ANG 
9 T-G-C . . . . . . . . . . . . . . . . . .  C . . . . . . . . . . . . . . . . .  JH 5 
HisThrP roGlnGlyProLeuTyrSer  PheAspSer  TrpGlyGlnGlyThrLeuVa iThrValSe r Set 
KER CACAC TCCCACAC TG TATTAC TATGGG TTCGACTCC TGGGC4:CAAGGAACCCTGGTCACCGTCTCC TCA KER 
Dxpl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  JH 5 
Figure 3. The sequences ncoding the deduced CDR3 of each of the rearranged V.5 genes compared with germline D. and J. minigene sequences 
having the highest nucleic acid sequence homology. All sequences are identified (right and left). (N-D-N) Column of sequences presumed tobe generated 
from D. minigenes and N-sequence insertions. (]H Segments) Column of sequences ncoded by a rearranged J, minigene. Above ach sequence is the 
deduced amino acid sequence. The germline D. and J, minigenes with highest nucleic acid sequence homology are listed below each sequence. (.)
Indicates sequence homology. 
were encoded by J.4, two (ANG and KER) by JH5, and two 
(CAV and PET) by J.6 (Fig. 3). 
Discussion 
We examined the leukemia cells from 68 randomly selected 
patients that satisfied clinical and diagnostic criteria for 
CD5 + B cell CLL. This group of CLL patients was noted 
to have a mean age and sex distribution comparable with that 
noted in earlier surveys of patients with this disease (39, 42). 
Furthermore, FACS | analyses demonstrated that the leukemia 
cells from each patient coexpressed pan-B cell surface antigens, 
CD5 and K or k Ig L chains. Of these CLL samples, we found 
that 7 (10%) had Ig gene rearrangements involving the V.5 
gene family. Nucleic acid sequence analyses of these Ig V. 
genes did not reveal evidence for intraclonal diversity or Ig 
somatic mutations. Instead, genetic polymorphism apparently 
accounts for some of the differences noted in V.5 genes de- 
tected in our survey. For example, the conservative base change 
in the codon at position 7 of the V.32 used by some of the 
CLL (Fig. 2) also was observed in the V,32 genes of two 
of three normal individuals examined by Sanz et al. (34). 
Moreover, all V.5 genes detected in this survey shared >98% 
nucleic acid sequence homology with known or suspected 
germline genes. This paucity of substantial somatic diversifi- 
cation in the rearranged V.5 genes noted in this study is 
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comparable with that of most other V. or VL genes found 
expressed in this disease (18-26). 
In contrast with previous reports on the V.5 genes rear- 
ranged in CLL (31), V.32 and not V~251 was the most fre- 
quently rearranged V.5 gene detected in our survey. Initially, 
V.32 was assumed to be a pseudogene due to a termination 
codon at amino acid position 82B (31, 35). However, Sanz 
et al. (34) reexamined the original V.32 clones and found 
errors in the reported sequence, allowing these investigators 
to conclude that V.32 was in fact functional. The rearranged 
V.32 genes observed in the current survey also lack any ter- 
mination codons and appear functional. In view of the finding 
that many individuals apparently lack the V.32 germline 
band, the relatively frequent use of V,32 in CLL appears 
remarkable. Indeed, the absence of the V.32 germline band 
may indicate that a relatively high proportion of individuals 
do not possess this Ig V gene in their germline DNA. How- 
ever, other explanations are possible, including polymorphisms 
affecting the restriction sites in and around V.32 and, at 
least in the current survey, Ig gene rearrangements and/or 
deletions by the leukemia cells studied. 
In any case, it is unlikely that we failed to detect rearranged 
V.251 genes in our survey that incurred extensive and 
selected somatic mutations. We performed Southern blot anal- 
yses using washing conditions that allow for detection of rear- 
ranged V. genes that share >80% homology with V.251. 
In addition, over half of the VH251 probe used in these anal- 
yses corresponded to the 5' flanking region and intron of the 
V.251 gene, regions not subject o selected Ig somatic mu- 
tation. Furthermore, using the V.251 probe we detected 
both V,32 and V.15, V.5 genes having 95 and 86% coding 
region nucleic acid sequence homology with V.251, respec- 
tively. Finally, PCR on all leukemia samples using oligonu- 
cleotides to amplify V.5 genes juxtaposed with J. demon- 
strated that only those DNA samples that had V.5 gene 
rearrangement bySouthern also generated PCR products that 
hybridized with oligonucleotides or full-length DNA probes 
for V.251 and related V.5 genes. 
These results contrast markedly with those recently reported 
by Cai et al. (32, 33), indicating that highly mutated V.251 
genes frequently are expressed in human B cell CLL. Earlier 
reports indicated that VH251 gene may be rearranged in the 
leukemia cells of 30% of the patients with this disease (31). 
More importantly, nucleic acid sequence analyses revealed ex- 
tensive numbers of base substitutions from the putative germ- 
line VH251 sequence. Moreover, the noted pattern of non- 
conservative base substitutions in the V.251 gene used by 
these CLL B cells was typical of Ig V genes expressed in sec- 
ondary immune responses to antigen (32, 33). In contrast, 
we found that only 2 of 68 CLL cell samples use V.251, and 
that these two apparently express this gene with little or no 
somatic mutation. 
Such differences may reflect heterogeneity within what cur- 
rently is considered B cell CLL. Subgroups of CLL may exist 
that arise from different B cell lineages and/or stages of B 
cell differentiation. Such differences may be reflected in the 
Ig V genes used by each subgroup. Already, we have noted 
that CD5- B cell CLL, in contrast with CD5 + B cell CLL, 
may display intraclonal diversity in their expressed Ig V genes 
(25, 53). Although both the current survey and that of Cai 
et al. (32, 33) examined CD5 + B cell CLL, there also may 
exist subgroups within this category of CLL that express Ig 
similar to that found in the primary (e.g., nonmutated) versus 
secondary (e.g., mutated) humoral immune response. Ar- 
guably, the leukemia cells in the former category may be those 
that express "natural" or polyreactive autoantibodies that fre- 
quently are detected in CD5 + B cell CLL (3-5). On the 
other hand, those CLL in the latter category may originate 
from B cells previously selected to express Ig with affinity 
for some unknown environmental or self-antigen(s). Antigen 
selection may not be unique to this subgroup, however. Re- 
cent Ig chain mixing studies employing murine transfectomas 
have indicated that the polyreactive binding activity of Ig 
encoded by nonmutated Ig V genes also may be a selected 
specificity (54). In addition, as demonstrated in this survey, 
it is not likely that the observed ifferences in the extent of 
observed Ig mutation depends upon expression of Ig V genes 
of the VH5 subgroup, in particular V.251. Rather, there may 
exist subsets of CD5 + B cell CLL that have differences in 
their cytogenesis and/or etiopathogenesis. Comparison of B 
cell CLL that express nonmutated versus highly mutated Ig 
V genes may reveal features that can be used to discriminate 
between these two types of leukemias, possibly allowing us 
to define subsets of CLL that have different clinical features 
and/or therapeutic requirements. 
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